IJBPAS, November, 2025, 14(11): 6075-6086

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

THE ROLE OF ARTIFICIAL INTELLIGENCE IN MEDICAL DEVICE AS PER US FDA: REGULATORY CONSIDERATION AND INNOVATIVE APPROACHES

GEORGE P[1] AND KAMARAJ R[2*]

[1,2*]Department of Pharmaceutical regulatory affairs, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India-603203

***Corresponding Author: Dr. Kamaraj Raju: E Mail: kamarajr@srmist.edu.in**

Received 18th July 2024; Revised 25th Sept. 2024; Accepted 5th Nov. 2024; Available online 1st Nov. 2025

https://doi.org/10.31032/IJBPAS/2025/14.11.9582

ABSTRACT

Artificial intelligence (AI) has the potential to significantly improve healthcare by providing individualized therapies and improving diagnostic accuracy when integrated with medical devices. This study investigates the application of artificial intelligence (AI) in medical devices, with a particular emphasis on the FDA's creative techniques and regulatory considerations. In order to assure safety and efficacy, the FDA's regulatory framework classifies AI-based medical devices into Class I, II, and III based on risk, using procedures including 510(k) clearance, premarket approval (PMA), and the De Novo pathway. The notion of Software as a Medical Device (SAMD) underscores the significance of regulatory supervision in the context of AI-powered applications. The many uses of AI in healthcare are demonstrated by AI-based products, such as clinical decision support systems, wearable health monitors, and diagnostic imaging tools. Given the adaptive nature of AI algorithms and potential biases in the algorithms, the FDA places a strong emphasis on post-market surveillance to address continuing safety and efficacy. By assessing the developer's procedures rather than the product itself, cutting-edge FDA programs like the Digital Health Software Precertification. Program seek to expedite the approval process. In order to standardize standards and guarantee that AI devices created elsewhere may satisfy American regulations, the FDA also promotes cooperation with industry participants, medical professionals, and

international regulatory organizations. These initiatives strive to strike a compromise between the strict patient safety regulations and the need for innovation, encouraging the creation of AI-integrated medical devices that improve healthcare while upholding high safety requirements

Keywords: Artificial Intelligence (AI), Healthcare, Individualized therapies, Diagnostic accuracy, Medical devices, FDA (Food and Drug Administration), Regulatory considerations, 510(k) clearance, Class I, II, III (risk classification), Software as a Medical Device (SAMD)

INTRODUCTION

Computer algorithms that replicate cognitive functions like studying and solving issues are referred to as artificial intelligence. Artificial machine learning neural networks are versatile mathematical frameworks that employ multiple methods to uncover complex nonlinear relationships within large datasets, now commonly known as big data. These networks serve as the fundamental building blocks for modern systems **[1]**. AI integration in medical devices offers substantial advantages in a number of areas related to the provision of healthcare. Improved diagnosis accuracy is one of the most convincing benefits. More rapidly and precisely than human experts, AI algorithms can process and understand enormous amounts of medical data. This can lead to the earlier discovery of diseases and ailments, which can improve patient outcomes and lower healthcare costs. Artificial Intelligence additionally enables personalized medicine by evaluating unique patient data, including genetics, medical history, and real-time physiological data, to customize treatment regimens that are less harmful and more successful. Artificial intelligence (AI) is being used extensively in healthcare. To comprehend clinical documentation and the significance of physician documentation, natural language processing techniques are applied. Convolutional neural networks are useful for estimating the structure of molecules and identifying promising pharmaceutical options for the treatment of diseases. A similar pattern for image classification problems has been followed by several machine learning (ML) approaches during the last ten years **[2]**. Before the parent firm can legally sell medical hardware or software in the US, it is required to undergo FDA review. There are three levels of clearance for clinically oriented "AI/ML-based algorithms set by the regulatory body: 510(k), premarket approval, and the de novo pathway.

Certain requirements must be met for each level of clearance to be awarded" **[3]**. There are many reasons to investigate artificial intelligence (AI) in medical devices, but one of the main ones is to find out how it relates

to US FDA regulations. It seeks to educate all relevant parties—including regulators, legislators, and healthcare professionals and device manufacturers—about the significant effects AI technology can have on boosting overall patient care, personalizing treatment regimens, and increasing diagnostic accuracy. FDA regulatory frameworks sheds light on the strict specifications for AI-powered devices, such as risk-based classification, pre-market approval procedures, and continuous post-market monitoring **[4]**. Certain requirements must be met for each level of clearance to be awarded **[5]**. The FDA was selected as an example for additional examination because it has demonstrated leadership in the deployment of AI-based medical technologies and has established a particular framework for these algorithms. For medical device licensing, the FDA imposes strict regulations due to the high-risk nature of these products and the unknown effects of applying AI for medical decision making and data analysis. For medical devices to be sold and used lawfully in the US, they must first receive clearance or approval from the "US Food and Drug Administration (FDA)". When developing, approving, and marketing gadgets to consumers for use in healthcare settings, FDA clearance offers a fair level of trust to the customer regarding the legitimacy and safety of the device when it comes to employing it in such a delicate area **[6]**.

SOFTWARE AS MEDICAL DEVICE

"A number of AI/ML-based medicinal products need to be reviewed by regulatory bodies. In the United States, for instance, a medical device is described as an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related object under Section 201(h) of the Federal Food, Drug, and Cosmetic Act". Also, this includes any component, part, or accessory that is intended for use in assessing illnesses or other conditions, as well as in preventing, reducing, addressing, or curing conditions. it includes any part that is not dependent on metabolization to fulfil its primary intended purposes and does not accomplish them through chemical action within or on the human body. Certain AI/ML-based software functions "(such certain clinical decision support software under Section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act)" may not be considered devices under U.S. law, while some may. The program that is considered a medical device in and of itself, "without being part of a hardware medical device," is specifically referred to as "Software as a Medical Device" (SAMD). Although the FDA has committed to the SAMD build, not everyone agrees with it. In the sections that follow, we will look at how the SAMD construct might be improved by

looking beyond a product-centric perspective **[7]**.

AI BASED MEDICAL DEVICES

"Diagnostic imaging devices [8]: MRI (Magnetic Resonance Imaging), CT (Computed Tomography) scanners, and X-ray machines can all be made more accurate with the use of machine learning algorithms". Algorithms for machine learning, for example, can be used to automatically detect and interpret anomalies in medical imaging. Tumors and lesions are common examples of these anomalies.

Certified Wearable health monitors: Fitbits and other wearable health monitors can function as medical devices with the appropriate certification. "They often track and examine health data, such heart rate, sleep patterns, and activity levels, using machine learning algorithms". These tools can provide information about a person's health and assist in spotting possible health hazards.

Clinical decision support systems: Machine learning techniques are often used in clinical decision support systems to help physicians make more informed and precise treatment decisions. ML algorithms, for instance, can be used to evaluate patient data and generate therapy suggestions for budget planner users based on that data.

Medical robots: ML algorithms are used by medical robots to enhance their performance in surgical procedures and other medical duties. Robotic surgical systems can be made more accurate and precise with the use of specific machine learning algorithms.

Drug delivery devices: Drug delivery devices like insulin pumps and implanted drug delivery systems are also optimized through the application of machine learning algorithms. ML models, for example, can be used to evaluate patient data and modify medication dosages

Ensuring safety and efficacy of AI integrated medical device

Medical devices with AI integration require a number of critical approaches to ensure their safety and effectiveness. Building dependable AI models requires, first and foremost, using sound design and development techniques, such as Good Machine Learning Practices (GMLP) **[9]**. To maintain consistent performance across many situations, this involves doing iterative testing and validation and using diverse datasets to prevent bias. The function of regulatory oversight is crucial, as risk assessment aids in identifying the suitable regulatory pathway and pre-market evaluations guarantee that devices adhere to safety standards. For patients and clinicians to comprehend and have confidence in AI-based judgments, transparency and explainability are essential; AI algorithms should be comprehensible. Informed use is also facilitated by clear instructions and labelling is essential to have post-market

surveillance methods and continuous monitoring in place to identify abnormalities and incorporate customer feedback into ongoing improvements. Additionally crucial are ethical and prejudice considerations; in order to guarantee fair results for all patient populations, developers should actively seek to detect and reduce bias in AI systems **[10]**.

Industry stakeholders working together and pursuing standardization facilitate the exchange of best practices and encourage uniformity among AI devices. Stakeholders may improve patient care and results while lowering risks by concentrating on these areas to increase the safety and effectiveness of AI-integrated medical devices **[11]**.

Table 1: Classification of medical devices

	Risk	Description	Regulatory Requirements:	Examples
CLASS 1	LOW	Class I devices are regarded to offer minimal risk to patients and are subject to the least regulatory control. They are often simpler in design and function.	Premarket notification (510k), GMP, Most Class I devices do not require premarket approval or a 510(k) submission.	1.AI algorithms used for maintaining patient information or scheduling without direct clinical effects. 2.Fundamental instruments that offer broad suggestions grounded in non-clinical information
CLASS 2	MODERATE	Frequently used for therapeutic or diagnostic purposes, Class II devices are more dangerous than Class I ones and need more stringent regulations to guarantee efficacy and safety. (8)	Premarket Notification [510(k)]: Manufacturers are required to show that the product is essentially the same as an already-available, lawfully marketed product. And post-market surveillance, and labelling requirements.	Artificial intelligence (AI) techniques that help radiologists find possible anomalies in an X-ray or MRIs are examples of systems that analyse medical imagery.
CLASS 3	HIGH	Class III devices are deemed high-risk and frequently necessitate the strictest regulatory controls because they are vital for maintaining life or detecting serious conditions	Premarket approval (PMA), substantial clinical data must be used to prove its efficacy and safety. Rigorous Evaluation	Autonomous Diagnostic Systems Complex Therapeutic Systems

Types of FDA approvals for AI based medical device

510(k) clearance

"An algorithm receives a 510(k) clearance if it is demonstrated to be at least as safe and efficient as a comparable, legally marketed algorithm". Significant equivalency proof must be included in the application by the submitter requesting this approval. The algorithm awaiting approval cannot be lawfully commercialized unless it is approved as substantially equivalent to the

other algorithm **[12]**. The regulatory procedure known as 510(k) is another name for premarket notice. "510(k)" designates the Medical Device Amendments of 1976's foundational provision. The 510(k) form is not actually a form; rather, it is a submission to the FDA proving that a device is essentially identical to an already-existing, lawfully marked device and is as safe and effective. Manufacturers requesting device clearance through the 510(k) process must show that the device is "substantially equivalent" to products already on the market, as stated in the Code of Federal Regulation (Title 21, Section 807); this process is typically quicker and less expensive than the premarket approval (PMA) process **[13]**. Clinical trials are typically not necessary for devices certified under the 510(k) process; however, this is still a topic of significant debate. July 2011, the in a report on the 510(k) process that was commissioned by the FDA, the Institute of Medicine found that while it establishes "substantial equivalency" to an existing product, it does not guarantee safety and effectiveness. Consequently, they suggested doing away with this procedure. In light of this, the makers of specific 510(k) devices must now supply sophisticated clinical trial data to back up their clearance; nevertheless, this requirement is not anticipated to be as stringent as the PMA procedure **[14]**.

"PMA PROCESS"

"PMAis the FDA process of scientific and regulatory review to independently evaluate the safety and effectiveness of Class III medical devices PMA approval requires a reasonable assurance that the device is safe and effective for the intended use, supported by credible scientific evidence". This is the evidential standard. For medications or biologics, which need strong proof of safety and efficacy, there is a somewhat different criterion. It has been determined that at least two positive randomized controlled trials satisfy the significant evidence criterion for pharmaceuticals and biologics **[15]**.

PMA application flow chart for AI medical device [16, 17]


AI medical device classification
Pre-submission meeting with FDA
PMA application preparation
Device description
Design control documentation
Non-clinical data
Clinical data
Performance characteristic
Labelling and usage guidelines
Quality system compliance
FDA review and feedback
Approval

DE NOVA PATHWAYS

Medical devices that meet the criteria for safety and effectiveness, but do not have a previously approved device to serve as a reference, can be classified as either class I or class II using the De Novo approach **[18]**. This path was developed as a substitute to the standard dangerous class III categorization. When a De Novo is granted, a new rule is established for the particular device as well as, more broadly, for the general type of device and its intended purpose. This new regulation is then used to regulate subsequent devices, so only the first one is considered a De Novo. "Through the De Novo method, a number of AI device types have been categorized as class II, establishing particular, published special regulations for the relevant product class.

Examples of product classes include radiological computer-aided diagnosis (cadx) for lesions suspected for cancer and computer-aided detection (cade) for lesions utilizing optical colonoscopy" **[19]**. The first digital pathology AI device, which is more broadly defined as "software algorithms to provide information to the user about presence, location, and characteristics of areas of the image with clinical implications, is an example of how de Novo submissions can also establish broader product classes". The objective of the data this device provides is to assist the user in diagnosing a medical condition **[20]**.

POST MARKET SURVEILLANCE AND MONITORING

The goal of the FDA's post-market surveillance (PMS) program for AI-driven medical devices is to guarantee the long-term efficacy and safety of these products. The FDA stresses continuous monitoring to gather real-world data and performance because AI algorithms are dynamic and can adapt over time. Draft guidelines suggest a preset change control approach to manage software modifications without compromising safety. The regulatory framework takes adaptive algorithms into account and incorporates premarket review processes **[21]**.

Achieving an efficient PMS requires both proactive and reactive monitoring. Proactive surveillance uses real-time data collection to predict possible problems, while reactive surveillance reacts to unfavourable occurrences. For the purpose of reporting and examining adverse occurrences connected to medical devices, the MAUDE database is essential. Implementing active monitoring for new technologies, utilizing formal documentation for PMS initiatives, and pre-market surveillance to identify early concerns are examples of successful PMS tactics. Ongoing FDA research and stakeholder collaboration are addressing issues like controlling algorithmic bias and guaranteeing generalizability across clinical contexts. Overall, a balanced approach to

innovation and safety is emphasized by the FDA's changing standards on AI-driven medical devices, which use real-world data to continuously enhance device performance and patient outcomes **[22]**.

FDA approved successful AI- integrated medical device in the market

The FDA has approved a number of AI-integrated medical devices that have had a significant impact on the healthcare industry. The idx-DR System, approved in April 2018, is a ground-breaking advancement that uses AI to autonomously detect diabetic retinopathy from retinal images without the need for human interpretation **[23]**. The Arterys Cardio AI, approved in October 2021 **[24]**, uses AI to automate the interpretation of MRI data for evaluating heart function, thereby streamlining cardiac imaging workflows. The Viz.ai software helps identify and prioritize suspected large vessel occlusions in stroke patients, improving diagnostic speed and efficiency (FDA, 2018). Zebra Medical Vision's healthpnx, approved in 2019 **[25]**.

Innovative approaches

The FDA is successfully regulating AI in medical devices by utilizing a number of cutting-edge strategies. The Digital Health Software Precertification Program is one such project that seeks to expedite the approval process for new AI advancements by assessing the software developer's procedures rather than the product itself. The FDA is also investigating regulatory frameworks for AI models that are adaptive, meaning they can learn and adjust over time Without compromising efficacy or safety. To further comprehend the consequences of AI in healthcare and create efficient regulatory regulations, the agency is also promoting a collaborative atmosphere with industry stakeholders, medical experts, and patients. To test novel regulatory strategies for ai technology, the FDA also regularly publishes guidance guidelines and launches pilot projects, collecting information and insights to improve regulatory procedures. A crucial strategy for standardizing standards and guaranteeing that ai created outside may effectively satisfy us regulatory criteria is international collaboration with other regulatory organizations. These endeavors aim to maintain a balance between the requirement for patient safety and product efficacy and the innovation in ai-driven medical devices **[26, 27]**.

“Specific regulation for AI based medical device”

In recognition of the particular difficulties faced by AI-based medical devices, the FDA has created special rules. The FDA works with the International Medical Device Regulators Forum (IMDRF) to develop standards centered on clinical evaluation and risk assessment. These devices are frequently “classified as Software as a

Medical Device (SaMD)". With a focus on patient-centered oversight, transparency, and real-world performance monitoring, the FDA announced an "AI/ML-based SaMD Action Plan in January 2021", stressing responsible AI innovation. In addition, the FDA suggests a set of best practices for algorithm training, data management, validation, and ongoing monitoring called Good Machine Learning Practices (GMLP). It is being investigated if AI devices can adapt over time by following a predefined change control plan in which producers pre-emptively designate future modifications and control, cybersecurity is essential.

CONCLUSION

Significant advantages come from the use of artificial intelligence (AI) into medical devices, such as more tailored care and diagnostic precision. These AI-powered gadgets are regulated by the FDA using a systematic framework that divides them into Class I, II, and III according on risk tolerance. Devices may go through several regulatory procedures, including the De Novo pathway, PMA, and 510(k) clearance. To ensure continued safety and efficacy, post-market surveillance must be ongoing and must address concerns such as algorithmic bias and performance in various clinical scenarios. The Digital Health Software Precertification Program and international collaboration are two examples of innovative initiatives that strive to strike a balance between innovation and patient safety, advancing the field while upholding strict standards

REFERENCE

[1] Russell S, Bohannon J (2015) Artificial intelligence. Fears of an AI pioneer. Science 349:252

[2] Miller DD, Brown EW (2018) Artificial intelligence in medical practice: the question to the answer? Am J Med 131:1 29–133

[3] PwC. No longer science fiction, AI and Robotics Are Transforming Healthcare. Accessed May 30, 2023. https:// www.pwc.com/gx/en/industries/healthcare/ publications/ai-robotics-new-health/transforming-healthcare.html

[4] Iroju OG, Olaleke JO. A systematic review of natural language processing in healthcare. Int J Inf Technol Comput Sci. 2015;7:44-50. doi:10.5815/ijitcs.2015.08.07

[5] FDA. Premarket Notification 510(k). https://www.fda.gov/medical-devices/ premarket-submissions/premarket-notification-510k (2020).

[6] FDA. Premarket Approval (PMA). https://www.fda.gov/medical-devices/premarketsubmissions/premarket-approval-pma (2019). 16. FDA. De Novo Classification Request https://www.fda.gov/medical-devices/ premarket-submissions/de-novo-classification-request (2019)

[7] FDA. Proposed regulatory framework for modifications to artificial intelligence/ machine learning (ai/ml)-based Software as

a Medical Device (SaMD). Discussion Paper and Request for Feedback. https://www.regulations.gov/document?D=FDA2019-N-1185-0001 (2019

[8] Gerke, S., Babic, B., Evgeniou, T. *et al.* The need for a system view to regulate artificial intelligence/machine learning-based software as medical device. *npj Digit. Med.* **3**, 53 (2020). https://doi.org/10.1038/s41746-020-0262-2

[9] Kramer, D. B., & McMahon, P. M. (2018). "Managing changes in medical devices: FDA's new framework for software modifications." *JAMA*, 320(18), 1843-1844. DOI: 10.1001/jama.2018.14109.

[10] Adadi, A., & Berrada, M. (2018). "Peeking inside the black-box: a survey on explainable artificial intelligence (XAI)." *IEEE Access*, 6, 52138-52160. http://dx.doi.org/10.1109/ACCESS.2018.2870052

[11] Topol, E. J. (2019). "High-performance medicine: the convergence of human and artificial intelligence." *Nature Medicine*, 25(1), 44-56.

[12] https://doi.org/10.1038/s41591-018-0300-7

[13] https://doi.org/10.1016/j.jvir.2015.05.028; https://doi.org/10.1038/s41746-020-00324-0

[14] https://doi.org/10.1016/j.jvir.2015.05.028

[15] Raab GG, Parr DH. From Medical Invention to Clinical Practice: The Reimbursement Challenge Facing New Device Procedures and Technol ogy– Part 1: Issues in Medical Device Assessment. J Am Coll Radiol 2006; 3:694–702. https://doi.org/10.1016/j.jacr.2006.02.005

[16] 21 CFR Part 814. Guidance for industry: providing clinical evidence of effectiveness for human drug and biological products.https://www.semanticscholar.org/paper/Guidance-for-Industry-Providing-Clinical-Evidence/7df72309c91f26554e69917a3814243fe4eb368e

[17] U.S. Food and Drug Administration [Internet]. HDE Approvals. Available From: http://www.fda.gov/MedicalDevices/ProductsandMedicalProce

[18] Abel DB, Farb A, Moynahan M. FDA Response to Medical DeiceRegulatory Challenges. Endovascular Today. March 2013: 57–61.

[19] U.S. Food and Drug Administration, "De Novo classification process (evaluation of automatic class III designation)- guidance for industry and FDA staff," (2021), https://www.fda.gov/media/72674/download

[20] Petrick N, Chen W, Delfino JG, Gallas BD, Kang Y, Krainak D, Sahiner B, Samala RK. Regulatory considerations for medical imaging AI/ML devices in the United States: concepts and challenges. J Med Imaging (Bellingham). 2023 https://doi.org/10.1007/978-1-0716-3195-9_23

[21]: U.S. Food and Drug Administration, "Paige prostate: FDA reclassification order,"

(2021)\https://in.search.yahoo.com/search?fr=mcafee&type=E210IN714G0&p=http%3A%2F%2Fwww.accessdata+.fda.gov%2Fcdrh_docs%2Fpdf17%2FDEN170022

[22] Xu, J., Glicksberg, B. S., Su, C., Walker, P., & Bian, J. (2021). "Identifying adverse drug events from social media posts using deep learning models." *Journal of Biomedical Informatics*, 118, 103795. https://doi.org/10.1007/s41666-020-00082-4

[23] Rieke, N., Hancox, J., Li, W., Milletari, F., Roth, H. R., Albarqouni, S., ... & Cardoso, M. J. (2020). "The future of digital health with federated learning." *npj Digital Medicine*, 3(1), 119. http://dx.doi.org/10.1038/s41746-020-00323-1

[24] Wiens, J., & Shenoy, E. S. (2018). "Machine learning for healthcare: on the verge of a major shift in healthcare epidemiology." *Clinical Infectious Diseases*, 66(1), 149-153. https://doi.org/10.1093/cid/cix731

[25] Abràmoff, M. D., Lavin, P. T., Birch, M., Shah, N., & Folk, J. C. (2018). "Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices." *npj Digital Medicine*, 1, 39. http://dx.doi.org/10.1038/s41746-018-0040-6

[26] Muthurangu, V., Lurz, J., Critser, P., Taylor, A. M., & Andriantsimiavona, R. (2019). "Utility of a cloud-based cardiovascular magnetic resonance network: preliminary evaluation of the Arterys system." *Journal of Cardiovascular Magnetic Resonance*, 21(1), 30. https://doi.org/10.1186/s12968-016-0271-0

[27] Repici, A., Badalamenti, M., Maselli, R., Correale, L., Radaelli, F., Rondonotti, E., & Hassan, C. (2020). "Efficacy of real-time computer-aided detection of colorectal neoplasia in a randomized trial." *Gastroenterology*, 159(2), 512-520. https://doi.org/10.1053/j.gastro.2020.04.062